Erratum: Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study (Journal of Clinical Oncology (2017) 35 (1411-1420) DOI: 10.1200/JCO.2016.69.9330);Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study

Journal of Clinical Oncology

Volumn 35, Issue 13, 2017, Pages 1411-1420

  Rosenthal, Adam N ^a   Fraser, Lindsay S M ^a   Philpott, Susan ^a   Manchanda, Ranjit ^c   Burnell, Matthew ^a   Badman, Philip ^a   Hadwin, Richard ^a   Rizzuto, Ivana ^a   Benjamin, Elizabeth ^a   Singh, Naveena ^b   Evans, D Gareth ^e   Eccles, Diana M ^f   Ryan, Andy ^a   Liston, Robert ^a   Dawnay, Anne ^d   Ford, Jeremy ^a   Gunu, Richard ^a   Mackay, James ^a   Skates, Steven J ^g   Menon, Usha ^a   Jacobs, Ian J ^a,h   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HEREDITARY TUMOR; HIGH RISK POPULATION; HUMAN; LAPAROSCOPY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OCCULT CANCER; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; UNITED KINGDOM; AGED; ALGORITHM; BLOOD; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECHOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; UTERINE TUBE TUMOR; VERY ELDERLY;

CA 125 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CA-125 ANTIGEN; COHORT STUDIES; EARLY DETECTION OF CANCER; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; ULTRASONOGRAPHY; UNITED KINGDOM;

EID: 85018316679     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.8830     Document Type: Erratum

References (31)

1. Rubin SC, Blackwood MA, Bandera C, et al: BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178:670-677, 1998
2. Alsop K, Fereday S, Meldrum C, et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654-2663, 2012
3. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associatedwith BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
4. Evans DG, Shenton A, Woodward E, et al: Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155, 2008
5. Ramus SJ, Song H, Dicks E, et al: Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 107:djv214, 2015
6. Song H, Dicks E, Ramus SJ, et al: Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 33:2901-2907, 2015
7. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 26:20-25, 2008
8. Candido-dos-Reis FJ, Song H, Goode EL, et al: Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 21:652-657, 2015
9. Marchetti C, De Felice F, Palaia I, et al: Riskreducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14:150, 2014
10. Finch AP, Lubinski J, Møller P, et al: Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547-1553, 2014
11. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010
12. Michelsen TM, Pripp AH, Tonstad S, et al: Metabolic syndrome after risk-reducing salpingooophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study. Eur J Cancer 45:82-89, 2009
13. Tuppurainen M, Kröger H, Honkanen R, et al: Risks of perimenopausal fractures: A prospective population-based study. Acta Obstet Gynecol Scand 74:624-628, 1995
14. Ryan J, Scali J, Carrière I, et al: Impact of a premature menopause on cognitive function in later life. BJOG 121:1729-1739, 2014
15. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 353:1207-1210, 1999
16. Rosenthal AN, Fraser L, Manchanda R, et al: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 31:49-57, 2013
17. Hogg R, Friedlander M: Biology of epithelial ovarian cancer: Implications for screening women at high genetic risk. J Clin Oncol 22:1315-1327, 2004
18. Stirling D, Evans DG, Pichert G, et al: Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23:5588-5596, 2005
19. Vasen HF, Tesfay E, Boonstra H, et al: Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 41:549-554, 2005
20. Hermsen BB, Olivier RI, Verheijen RH, et al: No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers: An observational followup study. Br J Cancer 96:1335-1342, 2007
21. Evans DG, Gaarenstroom KN, Stirling D, et al: Screening for familial ovarian cancer: Poor survival of BRCA1/2 related cancers. J Med Genet 46:593-597, 2009
22. Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327-340, 2009
23. Menon U, Ryan A, Kalsi J, et al: Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 33:2062-2071, 2015
24. Jacobs IJ, Menon U, Ryan A, et al: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 387:945-956, 2016
25. UK Familial Ovarian Cancer Screening Study: http://www.instituteforwomenshealth.ucl.ac.uk/womens-cancer/gcrc/ukfocss/UKFOCSS-Protocol-P2-v8-Oct-10-Website-20160525.pdf
26. Widschwendter M, Rosenthal AN, Philpott S, et al: The sex hormone system in carriers of BRCA1/2 mutations: A case-control study. Lancet Oncol 14: 1226-1232, 2013
27. Skates SJ, Mai P, Horick NK, et al: Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) 4:1401-1408, 2011
28. Aletti GD, Dowdy SC, Podratz KC, et al: Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol 197:676.e1-676.e7, 2007
29. Skates SJ, Greene MH, Buys SS, et al: Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk: Combined results from two screening trials. Clin Cancer Res [Epub ahead of print January 31, 2017]
30. Hyman DM, Long KC, Tanner EJ, et al: Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 126:224-228, 2012
31. Brain KE, Lifford KJ, Fraser L, et al: Psychological outcomes of familial ovarian cancer screening: No evidence of long-term harm. Gynecol Oncol 127: 556-563, 2012